These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 26918701)

  • 1. Increased serological cancer-associated biomarker levels at large bowel endoscopy and risk of subsequent primary cancer (†).
    Hvolris MH; Piper TB; Hammer E; Jørgensen LN; Olsen J; Rahr HB; Nielsen KT; Laurberg S; Christensen IJ; Brünner N; Johansen JS; Davis GJ; Dowell BL; Nielsen HJ
    Scand J Gastroenterol; 2016 Jul; 51(7):860-5. PubMed ID: 26918701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serological cancer-associated protein biomarker levels at bowel endoscopy: Increased risk of subsequent primary malignancy.
    Piper TB; Nielsen HJ; Christensen IJ
    Tumour Biol; 2022; 44(1):1-16. PubMed ID: 35180141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased serological, cancer-associated protein biomarker levels at diagnosis of large bowel adenoma: Risk of subsequent primary malignancy?
    Piper TB; Jørgensen LN; Olsen J; Nielsen KT; Davis G; Johansen JS; Jarle Christensen I; Nielsen HJ
    Acta Oncol; 2019; 58(sup1):S42-S48. PubMed ID: 30523734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma TIMP-1 and CEA as Markers for Detection of Primary Colorectal Cancer: A Prospective Validation Study Including Symptomatic and Non-symptomatic Individuals.
    Christensen IJ; Brünner N; Dowell B; Davis G; Nielsen HJ; Newstead G; King D
    Anticancer Res; 2015 Sep; 35(9):4935-41. PubMed ID: 26254391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood-based Biomarkers at Large Bowel Endoscopy and Prediction of Future Malignancies.
    Kring TS; Piper TB; Jørgensen LN; Olsen J; Rahr HB; Nielsen KT; Laurberg S; Davis G; Dowell B; Johansen JS; Christensen IJ; Brünner N; Nielsen HJ
    Biomark Cancer; 2015; 7():57-61. PubMed ID: 26526637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum YKL-40 in risk assessment for colorectal cancer: a prospective study of 4,496 subjects at risk of colorectal cancer.
    Johansen JS; Christensen IJ; Jørgensen LN; Olsen J; Rahr HB; Nielsen KT; Laurberg S; Brünner N; Nielsen HJ
    Cancer Epidemiol Biomarkers Prev; 2015 Mar; 24(3):621-6. PubMed ID: 25597749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals.
    Nielsen HJ; Brünner N; Jorgensen LN; Olsen J; Rahr HB; Thygesen K; Hoyer U; Laurberg S; Stieber P; Blankenstein MA; Davis G; Dowell BL; Christensen IJ; ;
    Scand J Gastroenterol; 2011 Jan; 46(1):60-9. PubMed ID: 20799911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum YKL-40, IL-6, CRP, CEA, and CA19-9 combined as a prognostic biomarker panel after resection of colorectal liver metastases.
    Peltonen R; Gramkow MH; Dehlendorff C; Osterlund PJ; Johansen JS; Isoniemi H
    PLoS One; 2020; 15(8):e0236569. PubMed ID: 32756596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of colorectal neoplasia: Combination of eight blood-based, cancer-associated protein biomarkers.
    Wilhelmsen M; Christensen IJ; Rasmussen L; Jørgensen LN; Madsen MR; Vilandt J; Hillig T; Klaerke M; Nielsen KT; Laurberg S; Brünner N; Gawel S; Yang X; Davis G; Heijboer A; Martens F; Nielsen HJ
    Int J Cancer; 2017 Mar; 140(6):1436-1446. PubMed ID: 27935033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of blood-based biomarker tests for early detection of colorectal neoplasia: Influence of blood collection timing and handling procedures.
    Lech Pedersen N; Mertz Petersen M; Ladd JJ; Lampe PD; Bresalier RS; Davis GJ; Demuth C; Jensen SØ; Andersen CL; Ferm L; Christensen IJ; Nielsen HJ
    Clin Chim Acta; 2020 Aug; 507():39-53. PubMed ID: 32272156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
    Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
    Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival.
    Nicolini A; Ferrari P; Duffy MJ; Antonelli A; Rossi G; Metelli MR; Fulceri F; Anselmi L; Conte M; Berti P; Miccoli P
    Arch Surg; 2010 Dec; 145(12):1177-83. PubMed ID: 21173292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of predictive markers for patients with advanced colorectal cancer.
    Byström P; Berglund Å; Nygren P; Wernroth L; Johansson B; Larsson A; Glimelius B
    Acta Oncol; 2012 Sep; 51(7):849-59. PubMed ID: 22974092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in the diagnosis of colorectal adenoma and cancer patients.
    Groblewska M; Mroczko B; Gryko M; Kędra B; Szmitkowski M
    Folia Histochem Cytobiol; 2010 Dec; 48(4):564-71. PubMed ID: 21478099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can preoperative CEA and CA19-9 serum concentrations suggest metastatic disease in colorectal cancer patients?
    Stojkovic Lalosevic M; Stankovic S; Stojkovic M; Markovic V; Dimitrijevic I; Lalosevic J; Petrovic J; Brankovic M; Pavlovic Markovic A; Krivokapic Z
    Hell J Nucl Med; 2017; 20(1):41-45. PubMed ID: 28315907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum markers in early-stage and locally advanced melanoma.
    Lugowska I; Kowalska M; Fuksiewicz M; Kotowicz B; Mierzejewska E; Koseła-Paterczyk H; Szamotulska K; Rutkowski P
    Tumour Biol; 2015 Nov; 36(11):8277-85. PubMed ID: 26002577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative analysis of the serum levels of NCC-ST-439, CEA and CA19-9 in patients with colorectal carcinoma.
    Iemura K; Moriya Y
    Eur J Surg Oncol; 1993 Oct; 19(5):439-42. PubMed ID: 8405479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does CEA and CA 19-9 combined increase the likelihood of 18F-FDG in detecting recurrence in colorectal patients with negative CeCT?
    Panagiotidis E; Datseris IE; Rondogianni P; Vlontzou E; Skilakaki M; Exarhos D; Bamias A
    Nucl Med Commun; 2014 Jun; 35(6):598-605. PubMed ID: 24681767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of determining tumor markers in patients with signs and symptoms of cancer.
    Trapé J; Sala M; Franquesa F; Ordeig JM; Soler-Bel JM; Bustamante E; Pérez R; Aligué J; Montesinos J; Arnau A; Ordeig-Villanueva R
    Clin Chem Lab Med; 2015 Feb; 53(3):485-91. PubMed ID: 25274947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic value of serum carcino-embryonic antigen, alpha fetoprotein and carbohydrate antigen 19-9 for colorectal cancer.
    Wang YR; Yan JX; Wang LN
    J Cancer Res Ther; 2014 Dec; 10 Suppl():307-9. PubMed ID: 25693941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.